96 related articles for article (PubMed ID: 3756224)
1. Increased (23R)-hydroxylase activity in patients suffering from cerebrotendinous xanthomatosis, resulting in (23R)-hydroxylation of bile acids.
Koopman BJ; Wolthers BG; Van der Molen JC; Nagel GT; Rutgers H; Strijtveen B; Kaptein B
Biochim Biophys Acta; 1986 Oct; 883(3):585-92. PubMed ID: 3756224
[TBL] [Abstract][Full Text] [Related]
2. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid.
Koopman BJ; Wolthers BG; van der Molen JC; Nagel GT; Kruizinga W
Biochim Biophys Acta; 1987 Feb; 917(2):238-46. PubMed ID: 3801500
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography.
Wolthers BG; Volmer M; van der Molen J; Koopman BJ; de Jager AE; Waterreus RJ
Clin Chim Acta; 1983 Jun; 131(1-2):53-65. PubMed ID: 6883710
[TBL] [Abstract][Full Text] [Related]
4. Capillary gas chromatographic determinations of urinary bile acids and bile alcohols in CTX patients proving the ineffectivity of ursodeoxycholic acid treatment.
Koopman BJ; Wolthers BG; van der Molen JC; Nagel GT; Waterreus RJ; Oosterhuis HJ
Clin Chim Acta; 1984 Sep; 142(1):103-11. PubMed ID: 6478619
[TBL] [Abstract][Full Text] [Related]
5. Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis.
Koopman BJ; Wolthers BG; van der Molen JC; Waterreus RJ
Clin Chim Acta; 1985 Oct; 152(1-2):115-22. PubMed ID: 4053393
[TBL] [Abstract][Full Text] [Related]
6. Identification of short side chain bile acids in urine of patients with cerebrotendinous xanthomatosis.
Kuramoto T; Furukawa Y; Nishina T; Sugimoto T; Mahara R; Tohma M; Kihira K; Hoshita T
J Lipid Res; 1990 Oct; 31(10):1895-902. PubMed ID: 2079611
[TBL] [Abstract][Full Text] [Related]
7. Bile acid profiles in bile, urine, and feces of a patient with cerebrotendinous xanthomatosis.
Kihira K; Shimazu K; Kuwabara M; Yoshii M; Takeuchi H; Nakano I; Ozawa S; Onuki M; Hatta Y; Hoshita T
Steroids; 1986; 48(1-2):109-19. PubMed ID: 3660436
[TBL] [Abstract][Full Text] [Related]
8. Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography.
Batta AK; Shefer S; Batta M; Salen G
J Lipid Res; 1985 Jun; 26(6):690-8. PubMed ID: 4031647
[TBL] [Abstract][Full Text] [Related]
9. Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26.
Salen G; Shefer S; Tint GS; Nicolau G; Dayal B; Batta AK
J Clin Invest; 1985 Aug; 76(2):744-51. PubMed ID: 4031069
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma bile alcohol glucuronides in patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid.
Batta AK; Salen G; Shefer S; Tint GS; Batta M
J Lipid Res; 1987 Aug; 28(8):1006-12. PubMed ID: 3668385
[TBL] [Abstract][Full Text] [Related]
11. Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.
Koopman BJ; Wolthers BG; van der Molen JC; van der Slik W; Waterreus RJ; van Spreeken A
J Inherit Metab Dis; 1988; 11(1):56-75. PubMed ID: 3128689
[TBL] [Abstract][Full Text] [Related]
12. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment.
Batta AK; Arora R; Salen G; Tint GS; Eskreis D; Katz S
J Lipid Res; 1989 Dec; 30(12):1953-62. PubMed ID: 2621422
[TBL] [Abstract][Full Text] [Related]
13. A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain.
Setoguchi T; Salen G; Tint GS; Mosbach EH
J Clin Invest; 1974 May; 53(5):1393-401. PubMed ID: 4825231
[TBL] [Abstract][Full Text] [Related]
14. Increased formation of ursodeoxycholic acid in patients treated with chenodeoxycholic acid.
Salen G; Tint GS; Eliav B; Deering N; Mosbach EH
J Clin Invest; 1974 Feb; 53(2):612-21. PubMed ID: 11344576
[TBL] [Abstract][Full Text] [Related]
15. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
Salen G; Shefer S; Tint GS
Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
[TBL] [Abstract][Full Text] [Related]
16. Reduction of urinary bile alcohol excretion and serum cholestanol in patients with cerebrotendinous xanthomatosis after oral administration of deoxycholic acid.
Wolthers BG; van der Molen JC; Walrecht H; Hesselmans LF
Clin Chim Acta; 1990 Dec; 193(3):113-8. PubMed ID: 2282689
[TBL] [Abstract][Full Text] [Related]
17. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
Batta AK; Salen G; Tint GS
Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis.
Salen G; Batta AK; Tint GS; Shefer S
Metabolism; 1994 Aug; 43(8):1018-22. PubMed ID: 8052141
[TBL] [Abstract][Full Text] [Related]
19. Serum bile acid profiles in cerebrotendinous xanthomatosis.
Beppu T; Seyama Y; Kasama T; Serizawa S; Yamakawa T
Clin Chim Acta; 1982 Feb; 118(2-3):167-75. PubMed ID: 7055978
[TBL] [Abstract][Full Text] [Related]
20. Role of the 26-hydroxylase in the biosynthesis of bile acids in the normal state and in cerebrotendinous xanthomatosis. An in vivo study.
Björkhem I; Fausa O; Hopen G; Oftebro H; Pedersen JI; Skrede S
J Clin Invest; 1983 Jan; 71(1):142-8. PubMed ID: 6848555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
